Pacific Biosciences of California (PACB) said Tuesday it was selected by the Davos Alzheimer's Collaborative as a technology partner for its North African Dementia Registry project.
The partnership will utilize Pacific Biosciences of California's sequencing technology to develop genetic insights into the factors contributing to Alzheimer's disease and dementia for future research, prevention, and treatment efforts, according to a company statement.
The collaboration is expected to address the underrepresentation of North African populations in dementia research and build a comprehensive dataset to further the research community's understanding of the disease, the company said.
Shares were up over 2% in recent Tuesday trading.
Price: 1.17, Change: +0.03, Percent Change: +2.63
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.